How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns: Table 1.
Authors:
- Lee S. SimonLSLee S. Simon
- C. Vibeke StrandCSC. Vibeke Strand
- Maarten BoersMBMaarten Boers
- Peter M. BrooksPBPeter M. Brooks
- Peter S. TugwellPTPeter S. Tugwell
- Claire BombardierCBClaire Bombardier
- James F. FriesJFJames F. Fries
- David HenryDHDavid Henry
- Larry GoldkindLGLarry Goldkind
- Gordon GuyattGGGordon Guyatt
- Andreas LaupacisALAndreas Laupacis
- Larry LyndLLLarry Lynd
- 8 September 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (9) , 2114-2121
Abstract
There is great concern about clearly defining benefit and risk in the context of both drug development and clinical practice. In view of this pressure, the OMERACT Executive identified the need to bring together clinical trialists, pharmacoepidemiologists, clinicians, clinical epidemiologists, statistical experts, and regulatory representatives to discuss different approaches to define risk and perhaps improved ways to express it. Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed.Keywords
This publication has 4 references indexed in Scilit:
- Observations from the OMERACT Drug Safety Summit, May 2008The Journal of Rheumatology, 2009
- Cochrane Handbook for Systematic Reviews of Interventions2008
- Grading quality of evidence and strength of recommendationsBMJ, 2004
- A toxicity index for comparison of side effects among different drugsArthritis & Rheumatism, 1990